Our findings indicate that biologics may influence Th2 immune responses, especially IL-13, which showed significantly elevated levels in biotreated patients, particularly those with allergic rhinitis (AR) and atopic dermatitis (AD). The gene discussed is IL13; the disease is atopic eczema.